Vident Advisory’s Quest Diagnostics DGX Stock Holding History

Vident Advisory’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.6M	Buy	8,164 +3,109	+62%	+$604K	0.01%	692
2025 Q4	$877K	Sell	5,055 -31	-0.6%	-$5.64K	0.01%	871
2025 Q3	$969K	Buy	5,086 +753	+17%	+$134K	0.01%	844
2025 Q2	$778K	Buy	4,333 +1,137	+36%	+$197K	0.01%	839
2025 Q1	$541K	Buy	3,196 +773	+32%	+$127K	0.01%	996
2024 Q4	$366K	Buy	2,423 +583	+32%	+$90.7K	0.01%	1086
2024 Q3	$286K	Buy	1,840 +171	+10%	+$25.5K	0.01%	1147
2024 Q2	$228K	Sell	1,669 -113,446	-99%	-$15.5M	0.01%	1232
2024 Q1	$15.3M	Buy	115,115 +108,523	+1,646%	+$14.1M	0.32%	92
2023 Q4	$909K	Buy	6,592 +4,871	+283%	+$640K	0.02%	591
2023 Q3	$210K	Buy	+1,721	New	+$229K	0.01%	1087

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Vident Advisory's DGX Position: Q1 2026 in Review

Vident Advisory increased its Quest Diagnostics (DGX) stake by 62% in Q1 2026, buying an estimated $604K and bringing the position to 8,164 shares worth $1.6M. The position accounts for 0.01% of the portfolio, ranked #692.

Vident Advisory first reported a position in DGX in Q3 2023 and has held it in 11 quarters since. The position peaked at $15.3M in Q1 2024. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

Vident Advisory held 8,164 shares of Quest Diagnostics worth $1.6M as of Q1 2026.
Vident Advisory bought 3,109 Quest Diagnostics shares in Q1 2026, an estimated $604K.
Quest Diagnostics made up 0.01% of Vident Advisory's portfolio in Q1 2026, its #692 holding.
Vident Advisory first reported a position in Quest Diagnostics in Q3 2023 and has held it in 11 quarters since.
Vident Advisory's Quest Diagnostics position peaked at $15.3M in Q1 2024.
1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.